COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study

DOI record: { "DOI": "10.2196/80263", "ISSN": [ "1929-073X" ], "URL": "http://dx.doi.org/10.2196/80263", "abstract": "<jats:title>Abstract</jats:title>\n <jats:sec sec-type=\"background\">\n <jats:title>Background</jats:title>\n <jats:p>Observation of COVID-19 rebound after nirmatrelvir plus ritonavir (NPR) has driven important questions surrounding one of the only direct-acting antiviral treatments for COVID-19.</jats:p>\n </jats:sec>\n <jats:sec sec-type=\"objective\">\n <jats:title>Objective</jats:title>\n <jats:p>The objective of this study was to examine the epidemiology of COVID-19 rebound among COVID-19–positive outpatients in the United States who independently decided whether or not to take NPR.</jats:p>\n </jats:sec>\n <jats:sec sec-type=\"methods\">\n <jats:title>Methods</jats:title>\n <jats:p>This prospective, decentralized observational cohort study was conducted from August 2022 through December 2023 and included frequent proctored COVID-19 rapid antigen tests and self-report symptom surveys for 15 days. The primary outcome was the incidence of viral and symptom rebound. Secondary outcomes included time to initial viral and symptom clearance, rebound probability among patients who cleared by day 15, and symptom frequency.</jats:p>\n </jats:sec>\n <jats:sec sec-type=\"results\">\n <jats:title>Results</jats:title>\n <jats:p>\n Of 917 consenting participants, 669 (73%) were eligible for inclusion in the analysis (n=443, 66% in the NPR group; n=226, 34% in the control group). The mean age was 46.1 (SD 12.9) years, 62.6% (n=419) of participants were female, and 49.2% (n=329) had at least one preexisting condition. Overall, 15-day cumulative incidence was higher in the NPR group than the control group for both viral (70/443, 15.8% vs 12/226, 5.3%) and symptom (73/443, 16.5% vs 19/226, 8.4%) rebound. Time to initial viral and symptom clearance was similar between groups, and among those who experienced clearance by day 15, the probability of viral rebound (NPR: 19.1%, 95% CI 15.1%-24.0% vs control: 7%, 95% CI 4.0%-12.6%;\n <jats:italic>P</jats:italic>\n &lt;.001) and symptom rebound (NPR: 47.7%, 95% CI 36.1%-60.8% vs control: 16.9%, 95% CI 10.9%-25.7%;\n <jats:italic>P</jats:italic>\n &lt;.001) was higher in the NPR group than the control group.\n </jats:p>\n </jats:sec>\n <jats:sec sec-type=\"conclusions\">\n <jats:title>Conclusions</jats:title>\n <jats:p>This study demonstrates that while COVID-19 rebound occurs in both NPR-treated and untreated outpatients, the incidence is higher in the NPR group.</jats:p>\n </jats:sec>", "article-number": "v15i15e80263", "author": [ { "ORCID": "https://orcid.org/0000-0002-6690-1552", "affiliation": [], "authenticated-orcid": false, "family": "Kueper", "given": "Jacqueline K", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "first" }, { "ORCID": "https://orcid.org/0000-0002-7035-4547", "affiliation": [], "authenticated-orcid": false, "family": "Kottilil", "given": "Kalyani", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0003-2208-7912", "affiliation": [], "authenticated-orcid": false, "family": "Quer", "given": "Giorgio", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0003-0919-9303", "affiliation": [], "authenticated-orcid": false, "family": "Chiang", "given": "Danielle C", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0003-2650-4357", "affiliation": [], "authenticated-orcid": false, "family": "Spencer", "given": "Emily G", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0002-6190-4199", "affiliation": [], "authenticated-orcid": false, "family": "Purushotham", "given": "Jyothi", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0003-1675-7094", "affiliation": [], "authenticated-orcid": false, "family": "Ramos", "given": "Edward", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Roumani", "given": "Leila", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0001-6431-5982", "affiliation": [], "authenticated-orcid": false, "family": "Andersen", "given": "Kristian G", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0002-1478-4729", "affiliation": [], "authenticated-orcid": false, "family": "Topol", "given": "Eric J", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0003-0119-0881", "affiliation": [], "authenticated-orcid": false, "family": "Pandit", "given": "Jay A", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0002-0674-5762", "affiliation": [], "authenticated-orcid": false, "family": "Mina", "given": "Michael J", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" } ], "container-title": "Interactive Journal of Medical Research", "container-title-short": "Interact J Med Res", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2026, 6, 2 ] ], "date-time": "2026-06-02T20:05:07Z", "timestamp": 1780430707000 }, "deposited": { "date-parts": [ [ 2026, 6, 2 ] ], "date-time": "2026-06-02T20:05:13Z", "timestamp": 1780430713000 }, "indexed": { "date-parts": [ [ 2026, 6, 2 ] ], "date-time": "2026-06-02T21:02:42Z", "timestamp": 1780434162445, "version": "3.54.1" }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2026, 6, 2 ] ] }, "language": "en", "member": "1010", "original-title": [], "page": "e80263-e80263", "prefix": "10.2196", "published": { "date-parts": [ [ 2026, 6, 2 ] ] }, "published-online": { "date-parts": [ [ 2026, 6, 2 ] ] }, "publisher": "JMIR Publications Inc.", "reference": [ { "key": "R1", "unstructured": "Surveillance and data analytics. US Centers for Disease Control and Prevention. URL: https://www.cdc.gov/covid/php/surveillance/index.html [Accessed 08-04-2024]" }, { "key": "R2", "unstructured": "Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. U.S. Food & Drug Administration. 2021. URL: https://web.archive.org/web/20211229172018/https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19 [Accessed 08-04-2024]" }, { "key": "R3", "unstructured": "FDA approves first oral antiviral for treatment of COVID-19 in adults. U.S. Food & Drug Administration. 2023. URL: https://tinyurl.com/2npxrtre [Accessed 25-05-2023]" }, { "key": "R4", "unstructured": "COVID-19 treatment clinical care for outpatients. U.S. Centers for Disease Control and Prevention. URL: https://tinyurl.com/yxjd5wxz [Accessed 08-04-2024]" }, { "key": "R5", "unstructured": "Living guidance for clinical management of COVID-19. World Health Organization. 2021. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2 [Accessed 08-04-2024]" }, { "key": "R6", "unstructured": "Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. 2024. URL: https://www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf_NBK570371.pdf [Accessed 29-04-2024]" }, { "DOI": "10.1056/NEJMoa2118542", "article-title": "Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19", "author": "Hammond", "doi-asserted-by": "publisher", "first-page": "1397", "issue": "15", "journal-title": "N Engl J Med", "key": "R7", "volume": "386" }, { "DOI": "10.1001/jama.2023.28254", "article-title": "Paxlovid is effective but underused-here’s what the latest research says about rebound and more", "author": "Rubin", "doi-asserted-by": "publisher", "first-page": "548", "issue": "7", "journal-title": "JAMA", "key": "R8", "volume": "331" }, { "DOI": "10.1001/jamahealthforum.2023.5044", "article-title": "Clinical risk and outpatient therapy utilization for COVID-19 in the Medicare population", "author": "Wilcock", "doi-asserted-by": "publisher", "issue": "1", "journal-title": "JAMA Health Forum", "key": "R9", "volume": "5" }, { "DOI": "10.1007/s40121-023-00910-1", "article-title": "Nirmatrelvir/ritonavir utilization for the treatment of non-hospitalized adults with COVID-19 in the national Veterans Affairs (VA) healthcare system", "author": "Appaneal", "doi-asserted-by": "publisher", "first-page": "155", "issue": "1", "journal-title": "Infect Dis Ther", "key": "R10", "volume": "13" }, { "key": "R11", "unstructured": "Rosen A . More Americans could benefit from Paxlovid for COVID infection. Johns Hopkins Bloomberg School of Public Health. 2024. URL: https://publichealth.jhu.edu/2024/why-more-people-should-be-prescribed-paxlovid-for-covid [Accessed 03-05-2026]" }, { "DOI": "10.15585/mmwr.mm7251a2", "article-title": "Evaluation of SARS-CoV-2 RNA rebound after nirmatrelvir/ritonavir treatment in randomized, double-blind, placebo-controlled trials - United States and international sites, 2021-2022", "author": "Harrington", "doi-asserted-by": "publisher", "first-page": "1365", "issue": "51", "journal-title": "MMWR Morb Mortal Wkly Rep", "key": "R12", "volume": "72" }, { "DOI": "10.1038/d41586-022-02121-z", "article-title": "COVID rebound is surprisingly common - even without Paxlovid", "author": "Callaway", "doi-asserted-by": "publisher", "journal-title": "Nature", "key": "R13" }, { "DOI": "10.1093/cid/ciad102", "article-title": "The Coronavirus disease 2019 rebound study: a prospective cohort study to evaluate viral and symptom rebound differences in participants treated with nirmatrelvir plus ritonavir versus untreated controls", "author": "Pandit", "doi-asserted-by": "publisher", "first-page": "25", "issue": "1", "journal-title": "Clin Infect Dis", "key": "R14", "volume": "77" }, { "DOI": "10.1002/rmv.2473", "article-title": "Efficacy and safety of Paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID-19: an updated meta-analysis and trial sequential analysis", "author": "Tian", "doi-asserted-by": "publisher", "issue": "5", "journal-title": "Rev Med Virol", "key": "R15", "volume": "33" }, { "DOI": "10.1016/j.jbi.2019.103208", "article-title": "The REDCap consortium: building an international community of software platform partners", "author": "Harris", "doi-asserted-by": "publisher", "journal-title": "J Biomed Inform", "key": "R16", "volume": "95" }, { "DOI": "10.1016/j.jbi.2008.08.010", "article-title": "Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support", "author": "Harris", "doi-asserted-by": "publisher", "first-page": "377", "issue": "2", "journal-title": "J Biomed Inform", "key": "R17", "volume": "42" }, { "DOI": "10.1093/jamiaopen/ooy012", "article-title": ": an open source Python package for producing summary statistics for research papers", "author": "Pollard", "doi-asserted-by": "publisher", "first-page": "26", "issue": "1", "journal-title": "JAMIA Open", "key": "R18", "volume": "1" }, { "key": "R19", "unstructured": "Davidson-Pilon C . lifelines, survival analysis in Python. Zenodo. 2023. URL: https://zenodo.org/records/10456828 [Accessed 03-05-2026]" }, { "DOI": "10.1016/j.jclinepi.2007.11.008", "article-title": "The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies", "author": "von Elm", "doi-asserted-by": "publisher", "first-page": "344", "issue": "4", "journal-title": "J Clin Epidemiol", "key": "R20", "volume": "61" }, { "DOI": "10.1093/cid/ciad696", "article-title": "Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared with propensity score-matched untreated individuals", "author": "Smith-Jeffcoat", "doi-asserted-by": "publisher", "first-page": "1175", "issue": "5", "journal-title": "Clin Infect Dis", "key": "R21", "volume": "78" }, { "DOI": "10.1056/NEJMoa2309003", "article-title": "Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19", "author": "Hammond", "doi-asserted-by": "publisher", "first-page": "1186", "issue": "13", "journal-title": "N Engl J Med", "key": "R22", "volume": "390" }, { "DOI": "10.1093/cid/ciac481", "article-title": "Rebound phenomenon after nirmatrelvir/ritonavir treatment of Coronavirus disease 2019 (COVID-19) in high-risk persons", "author": "Ranganath", "doi-asserted-by": "publisher", "first-page": "e537", "issue": "3", "journal-title": "Clin Infect Dis", "key": "R23", "volume": "76" }, { "DOI": "10.3390/v15040976", "article-title": "The antiviral effect of nirmatrelvir/ritonavir during COVID-19 pandemic real-world data", "author": "Petrakis", "doi-asserted-by": "publisher", "issue": "4", "journal-title": "Viruses", "key": "R24", "volume": "15" }, { "DOI": "10.1101/2022.08.04.22278450", "doi-asserted-by": "crossref", "key": "R25", "unstructured": "Wang L Volkow ND Davis PB Berger NA Kaelber DC Xu R . COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period. medRxiv. Aug 6, 2022:2022.08.04.22278450. [doi: 10.1101/2022.08.04.22278450] [Medline: 35982673]" }, { "DOI": "10.1186/s12879-024-09842-8", "article-title": "Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19", "author": "Camp", "doi-asserted-by": "publisher", "issue": "1", "journal-title": "BMC Infect Dis", "key": "R26", "volume": "24" }, { "DOI": "10.7326/M23-1756", "article-title": "SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy: an observational study", "author": "Edelstein", "doi-asserted-by": "publisher", "first-page": "1577", "issue": "12", "journal-title": "Ann Intern Med", "key": "R27", "volume": "176" }, { "DOI": "10.1006/bulm.2000.0181", "article-title": "Modeling immune responses with handling time", "author": "Pilyugin", "doi-asserted-by": "publisher", "first-page": "869", "issue": "5", "journal-title": "Bull Math Biol", "key": "R28", "volume": "62" }, { "DOI": "10.1128/jvi.01623-24", "article-title": "Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance", "author": "Phan", "doi-asserted-by": "publisher", "issue": "3", "journal-title": "J Virol", "key": "R29", "volume": "99" }, { "DOI": "10.1038/s41467-024-49458-9", "article-title": "A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy", "author": "Esmaeili", "doi-asserted-by": "publisher", "issue": "1", "journal-title": "Nat Commun", "key": "R30", "volume": "15" }, { "DOI": "10.1101/2023.05.30.23290747", "doi-asserted-by": "crossref", "key": "R31", "unstructured": "Perelson AS Ribeiro RM Phan T . An explanation for SARS-CoV-2 rebound after Paxlovid treatment. medRxiv. Jun 1, 2023:2023.05.30.23290747. [doi: 10.1101/2023.05.30.23290747] [Medline: 37398088]" } ], "reference-count": 31, "references-count": 31, "relation": {}, "resource": { "primary": { "URL": "https://www.i-jmr.org/2026/1/e80263" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study", "type": "journal-article", "volume": "15" }